Anteris Technologies reports one-year patient outcomes for DurAVR THV

Anteris Technologies (AVR) Global announced one-year results for patients treated with its proprietary, balloon expandable, DurAVR Transcatheter Heart Valve System. Rishi Puri, M.D. PhD presented the data at a late breaking clinical trial session at Sydney Valves: “Pioneering a New Class of Biomimetic TAVR with Sustained 1-Year Performance.” One-year Results Highlights: DurAVR THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area of 2.1 + 0.2 cm2, a Mean Pressure Gradient of 8.6 + 2.6 mmHg and Doppler Velocity Index of 0.58. At one-year, clinical safety outcomes show positive results with no valve or cardiovascular related mortality and importantly no prosthesis-patient mismatch reported in these small annuli patients. Current commercial devices have demonstrated rates between 11.2% to 35.3% PPM, a predictor of valve failure and disease progression.